Abattis receives Intl Class 5 Trademark for DefenZall in the U.S. and Taiwan

Jan 17 2013NewsGuard 100/100 Score

Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces it has been granted Intl Class 5 Trademark for DefenZall™ in Taiwan and the USA.

Mr. Mike Withrow , Chief Executive Officer on behalf of the Company, stated, "We are pleased to extend the intellectual property of the company as we grow our brands. This mark will be used to brand our proprietary Anti-Viral Nutraceutical Platform of products which are; DefenZall Daily™, DefenZall Immune Support™ and DefenZall Serious Defense™ They will be launched through our Canadian distributor Hedley Enterprises, on the Internet and via our Distributor in Hong Kong."

Source:

Abattis Bioceuticals Corp.

Posted in: Disease/Infection News | Pharmaceutical News

Tags: , , , ,

Comments (0)

Suggested Reading

Macrophage memory following COVID infection provides cross-virus protection
Octavalent intranasal flu vaccine proves effective in neutralizing both existing and emerging strains
New CDC report highlights disparities in flu hospitalization and vaccination
Innovative nasal spray and vaccine for respiratory virus protection
Study reveals high effectiveness of flu vaccines in children but highlights challenges with certain subtypes
Review highlights failures in global control strategies for bird flu transmission
Blowflies linked to bird flu spread in southern Japan
Electronic nudges improve flu vaccination rates in non-diabetic patients but fail to increase uptake in diabetics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Exclusive: Emails reveal how health departments struggle to track human cases of bird flu